Brief Summary
The purpose of this study is to assess the effect of delivering all anti-cancer medications during initial systemic therapy on outcomes in those undergoing treatment for metastatic colorectal cancer.
Intervention/Treatment
- Drug: mFOLFOX6
- Drug: Oxaliplatin
- Drug: Leucovorin
- Drug: Fluorouracil
- Drug: FOLFIRI
- Drug: CAPOX
- Drug: Capecitabine
- Drug: CAPIRI
- Drug: Irinotecan
Inclusion Criteria
- Signed informed consent obtained prior to any study specific procedures and willingness to comply with study requirements.
- Age greater than or equal to 18 years.
- Histologically confirmed, metastatic colorectal adenocarcinomacancer arising from mucus-producing glands in organs treated with less than or equal to 2 cycles of doublet chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells.
- ECOG performance status of 0-2.
- Life expectancy of greater than or equal to 3 months.
- Adequate major organ function to receive doublet chemotherapy as judged by the treating clinician.
- No contraindication to any of the 3 cytotoxic agents (5FU, oxaliplatin and irinotecan).
- Recent imaging of chest, abdomen and pelvis. It is recommended that this should be within 4 weeks of first chemotherapy dose (no more than 8 weeks).
Please note: Every patient enrolled in the study is then entered in the TRACC Registry to enable the data collection for the study.